Supernus is no longer a standalone central-nervous-system compounder waiting for the next product cycle. On the same morning the second-quarter print landed, the board signed a tax-free all-stock merger of equals with Indivior, the addiction-medicine company built around a long-acting buprenorphine injection. Supernus holders receive a fixed package of Indivior shares and finish as a minority in a renamed company that keeps the familiar ticker. The commercial engine underneath that paper is real: four growth products now carry most of the top line after years of generic erosion in the older epilepsy brands. The live debate is whether that engine is worth more as a minority claim on a larger, more concentrated platform than as a clean residual on Rockville's own earnings.
The quarter itself shows the trade-off. Total revenue climbed to $219 million as Qelbree volume, the ZURZUVAE collaboration with Biogen, and the ONAPGO Parkinson's infusion all contributed. Adjusted operating earnings still slipped to $31 million because selling costs tied to the Biogen partnership grew faster than sales. A non-cash APOKYN write-down of $55 million flipped reported results into a loss, which is accounting, not cash. Cash and marketable securities still rose to $372 million with no drawn bank debt. Growth is showing up; leverage on that growth is not.
Management raised full-year revenue guidance into a band that tops out near $890 million and still guided a GAAP operating loss after the impairment. The merger, if it closes in the fourth quarter, swaps that standalone print for a combined company that the two boards size at about $2 billion of revenue and a synergy target of $125 million. Indivior stockholders take a $1 billion special cash dividend funded partly with new term debt before close, so Supernus holders do not share that cash extraction. The open question is whether the market already treats the equity as deal paper, or whether it is still pricing a standalone CNS name that may never report another independent year.